The Latvian Medicines Verification Organization (LZVO) informs that in March the development and qualification of the Latvian Medicines Verification System (LZVS) 8.0 release will be completed.
Work on the updated version of LZVS began at the beginning of 2025, with development activities carried out during the spring and summer of 2025. Since the end of last year, the system qualification process has been ongoing, including joint user acceptance tests (jUAT) and interoperability tests (IOT). At the initiative of LZVO, limited-scale user acceptance tests (UAT) are also being carried out in March, including in the LZVS test environment.
The new LZVS release mainly contains technical changes, without significant impact on LZVS end-users. The interface version v5 will continue to be available for end-user connections.
The updated version 8.0 includes the following improvements:
- technical and security enhancements to ensure continued system stability and performance for system users;
- the possibility for WebGUI users to use an additional multi-factor authentication (MFA) option;
- resolution of previously identified minor issues.
It is planned that the LZVS 8.0 release will be deployed in the production environment at the beginning of May 2026.
LZVO expresses its gratitude to all parties involved for their contribution to ensuring that LZVS will continue to provide the highest level of security and enable system users to benefit from the most convenient and efficient IT solutions.
In addition to the improvements included in the 8.0 release, LZVO continues to invite end-users to contact their IT providers and timely switch to the new connection addresses in the OSC data center.